Is shorter also better in the treatment of Clostridioides difficile infection?
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články, pozorovací studie
PubMed
38661207
PubMed Central
PMC11144488
DOI
10.1093/jac/dkae119
PII: 7658082
Knihovny.cz E-zdroje
- MeSH
- antibakteriální látky * terapeutické užití aplikace a dávkování MeSH
- Clostridioides difficile * genetika účinky léků klasifikace MeSH
- fidaxomicin * terapeutické užití aplikace a dávkování MeSH
- klostridiové infekce * farmakoterapie mikrobiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- ribotypizace * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vankomycin * terapeutické užití aplikace a dávkování MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- Názvy látek
- antibakteriální látky * MeSH
- fidaxomicin * MeSH
- vankomycin * MeSH
OBJECTIVES: To assess the effectiveness of shortened regimens of vancomycin or fidaxomicin in the treatment of Clostridioides difficile infection (CDI). METHODS: Adult patients with CDI hospitalized from January 2022 to May 2023 were included in this observational study. In patients with CDI treated with vancomycin or fidaxomicin, antibiotic treatment was discontinued after either 5 or 7 days of vancomycin or 5 days of fidaxomicin if there was a clinical response and improvement in laboratory parameters. The control cohort was treated with the standard 10 day regimen of either vancomycin or fidaxomicin. The follow-up was 60 days. Causative C. difficile strains were characterized by ribotyping and toxin gene detection when available. RESULTS: Twenty-five patients (median age 76 years) received shortened treatment with vancomycin (n = 21), or fidaxomicin (n = 4). Five cases fulfilled the criteria for severe CDI. Twenty-three patients completed follow-up; two died from causes other than CDI, and two developed recurrent CDI (8.0%). Ribotypes (RTs) 001 and 014 were the most prevalent with 20% each. In two C. difficile isolates, binary toxin genes were detected (RTs 078 and 023). In the control group of 22 patients recurrent CDI developed in 5 patients (22.7%). No statistically significant differences were found between the groups. CONCLUSIONS: Shortened treatment regimens for CDI with vancomycin and fidaxomicin were shown to be effective in our cohort of patients compared with 10 days of treatment. The recurrence rate was lower in the study group. A larger, prospective, double-blind, randomized, multicentre study is needed to support our findings.
Zobrazit více v PubMed
Nicolaou K, Rigol S. A brief history of antibiotics and select advances in their synthesis. J Antibiot 2018; 71: 153–84. 10.1038/ja.2017.62 PubMed DOI
Zanella Terrier MC, Simonet ML, Bichard Pet al. Recurrent PubMed DOI PMC
Di Bella S, Ascenzi P, Siarakas Set al. PubMed DOI PMC
Finn E, Andersson FL, Madin-Warburton M. Burden of PubMed DOI PMC
van Prehn J, Reigadas E, Vogelzang HEet al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for PubMed DOI
Gerding DN, Muto CA, Owens RC Jr. Treatment of PubMed DOI
Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc 2011; 86: 1113–23. 10.4065/mcp.2011.0358 PubMed DOI PMC
Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: a systematic review of randomized controlled trials. Pharmacotherapy 2018; 38: 674–87. 10.1002/phar.2118 PubMed DOI
Michael M, Hodson EM, Craig JCet al. Short compared with standard duration of antibiotic treatment for urinary tract infection: a systematic review of randomised controlled trials. Arch Dis Child 2002; 87: 118–23. 10.1136/adc.87.2.118 PubMed DOI PMC
Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better. Ann Intern Med 2019; 171: 210–1. 10.7326/M19-1509 PubMed DOI PMC
McDonald LC, Gerding DN, Johnson Set al. Clinical practice guidelines for PubMed DOI PMC
Grayson ML, Kucers A, Crowe Set al. Kucers’ the Use of Antibiotics, 6th ed. Hodder Arnold, 2010.
Beneš J, Stebel R, Musil Vet al. Updated Czech guidelines for the treatment of patients with colitis due to PubMed
Fawley WN, Knetsch CW, MacCannell DRet al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for PubMed DOI PMC
Kim AH, Lee Y, Kim Eet al. Assessment of oral vancomycin-induced alterations in gut bacterial microbiota and metabolome of healthy men. Front Cell Infect Microbiol 2021; 11: 629438. 10.3389/fcimb.2021.629438 PubMed DOI PMC
Krutova M, Wilcox M, Kuijper E. PubMed DOI
Freeman J, Vernon J, Morris Ket al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent PubMed DOI
Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic-associated colitis due to PubMed DOI PMC
Eyre DW, Walker AS, Wyllie Det al. Predictors of first recurrence of PubMed DOI PMC
Wingen-Heimann SM, Davies K, Viprey VFet al. PubMed DOI
Krutova M, Nyc O, Matejkova Jet al. Molecular characterisation of Czech PubMed DOI
Kracík M, Dolinová I, Žemličková H. Ribotyping of PubMed DOI PMC
Krutova M, Matejkova J, Drevinek Pet al. Increasing incidence of PubMed DOI
